Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges

被引：18
作者：
Koutras, A. K. [1 ]
Starakis, I. [1 ]
Kyriakopoulou, U. [1 ]
Katsaounis, P. [1 ]
Nikolakopoulos, A. [1 ]
Kalofonos, H. P. [1 ]
机构：
[1] Univ Hosp Patras, Div Oncol, Dept Med, Rion, Greece
来源：
CURRENT MEDICINAL CHEMISTRY | 2011年 / 18卷 / 11期
关键词：
Bevacizumab; cetuximab; colorectal cancer; panitumumab; targeted therapy; GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; CETUXIMAB PLUS IRINOTECAN; MONOCLONAL-ANTIBODY; KRAS MUTATIONS; 1ST-LINE TREATMENT; TUMOR-GROWTH; PANITUMUMAB MONOTHERAPY; IONIZING-RADIATION; INDUCED ACTIVATION;
D O I：
10.2174/092986711795471338
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Treatment of metastatic colorectal cancer (mCRC) has progressed significantly over the last years, particularly with the introduction of targeted therapies. Two groups of agents targeting either the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF) have been integrated into clinical practice. Currently available agents with established role include the anti-EGFR monoclonal antibodies (mAbs) cetuximab/panitumumab and the anti-VEGF mAb bevacizumab. This review presents an update on the clinical studies evaluating the role of anti-EGFR and anti-VEGF agents in mCRC. Moreover, we provide current data regarding the mechanism of action and pathways mediating resistance to these agents. In addition, we present recent data with respect to biomarkers and we discuss future therapeutic strategies.
引用
收藏
页码：1599 / 1612
页数：14
相关论文
共 144 条
  • [1] Allegra C.J., 2008, J CLIN ONCOLOGY
  • [2] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado, Rafael G.
    Wolf, Michael
    Peeters, Marc
    Van Cutsem, Eric
    Siena, Salvatore
    Freeman, Daniel J.
    Juan, Todd
    Sikorski, Robert
    Suggs, Sid
    Radinsky, Robert
    Patterson, Scott D.
    Chang, David D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1626 - 1634
  • [3] Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study
    Andreyev, HJN
    Norman, AR
    Cunningham, D
    Oates, JR
    Clarke, PA
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) : 675 - 684
  • [4] [Anonymous], 2005, European medicines agency veterinary medicines and inspections, guideline on test procedures and acceptance criteria for new veterenary drug substances and new medicinal products chemical substances
  • [5] [Anonymous], SUMMARY PRODUCT CHAR
  • [6] Targeted treatments in colorectal cancer: state of the art and future perspectives
    Arnold, Dirk
    Seufferlein, Thomas
    [J]. GUT, 2010, 59 (06) : 838 - 858
  • [7] Asmis T., 2008, PANITUMUMAB CHEMOTHE
  • [8] Somatic mutations of EGFR in colorectal cancers and glioblastomas
    Barber, TD
    Vogelstein, B
    Kinzler, KW
    Velculescu, VE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) : 2883 - 2883
  • [9] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
    Baselga, J
    Pfister, D
    Cooper, MR
    Cohen, R
    Burtness, B
    Bos, M
    D'Andrea, G
    Seidman, A
    Norton, L
    Gunnett, K
    Falcey, J
    Anderson, V
    Waksal, H
    Mendelsohn, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) : 904 - 914
  • [10] Baselga J., 2006, J CLIN ONCOLOGY
12345678910